Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Role of Biologics in First-Line Treatment of Colorectal Cancer.

Mahipal A, Grothey A.

J Oncol Pract. 2016 Dec;12(12):1219-1228. Review.

PMID:
27943689
2.

EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.

Ålgars A, Sundström J, Lintunen M, Jokilehto T, Kytölä S, Kaare M, Vainionpää R, Orpana A, Österlund P, Ristimäki A, Carpen O, Ristamäki R.

Int J Cancer. 2017 Feb 15;140(4):922-929. doi: 10.1002/ijc.30507. Epub 2016 Nov 23.

3.

Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.

Queralt B, Cuyàs E, Bosch-Barrera J, Massaguer A, de Llorens R, Martin-Castillo B, Brunet J, Salazar R, Menendez JA.

Oncotarget. 2016 Dec 13;7(50):82185-82199. doi: 10.18632/oncotarget.11985.

4.

CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.

Zhang X, Shimodaira H, Soeda H, Komine K, Takahashi H, Ouchi K, Inoue M, Takahashi M, Takahashi S, Ishioka C.

Int J Clin Oncol. 2016 Dec;21(6):1091-1101. Epub 2016 Jul 19.

PMID:
27435270
5.

Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.

Veluchamy JP, Spanholtz J, Tordoir M, Thijssen VL, Heideman DA, Verheul HM, de Gruijl TD, van der Vliet HJ.

PLoS One. 2016 Jun 17;11(6):e0157830. doi: 10.1371/journal.pone.0157830. eCollection 2016.

6.

Successful Treatment with Modified FOLFOX6 and Panitumumab in a Cecal Cancer Patient Undergoing Hemodialysis.

Kobayashi M, Endo S, Hamano Y, Imanishi M, Akutsu D, Sugaya A, Ochi D, Moriwaki T, Hyodo I.

Intern Med. 2016;55(2):127-30. doi: 10.2169/internalmedicine.55.5113. Epub 2016 Jan 15.

7.

Correlation between DPYD gene variation and KRAS wild type status in colorectal cancer.

Kleist B, Kempa M, Meurer T, Poetsch M.

J Clin Pathol. 2016 Mar;69(3):204-8. doi: 10.1136/jclinpath-2015-202903. Epub 2015 Aug 17.

PMID:
26281864
8.

Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.

Troiani T, Napolitano S, Martini G, Martinelli E, Cardone C, Normanno N, Vitagliano D, Morgillo F, Fenizia F, Lambiase M, Formisano L, Bianco R, Ciardiello D, Ciardiello F.

Clin Cancer Res. 2015 Sep 15;21(18):4153-64. doi: 10.1158/1078-0432.CCR-15-0211. Epub 2015 May 27.

9.

Molecular markers predictive of chemotherapy response in colorectal cancer.

Shiovitz S, Grady WM.

Curr Gastroenterol Rep. 2015 Feb;17(2):431. doi: 10.1007/s11894-015-0431-7. Review.

10.

Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy.

Maus MK, Hanna DL, Stephens CL, Astrow SH, Yang D, Grimminger PP, Loupakis F, Hsiang JH, Zeger G, Wakatsuki T, Barzi A, Lenz HJ.

Pharmacogenomics J. 2015 Aug;15(4):354-62. doi: 10.1038/tpj.2014.73. Epub 2014 Dec 23.

11.

Targeting mTOR network in colorectal cancer therapy.

Wang XW, Zhang YJ.

World J Gastroenterol. 2014 Apr 21;20(15):4178-88. doi: 10.3748/wjg.v20.i15.4178. Review.

12.

Dose KRAS Mutation Status Affect on the Effect of VEGF Therapy in Metastatic Colon Cancer Patients?

Kim ST, Park KH, Shin SW, Kim YH.

Cancer Res Treat. 2014 Jan;46(1):48-54. doi: 10.4143/crt.2014.46.1.48. Epub 2014 Jan 15.

13.

The ErbB/HER family of protein-tyrosine kinases and cancer.

Roskoski R Jr.

Pharmacol Res. 2014 Jan;79:34-74. doi: 10.1016/j.phrs.2013.11.002. Epub 2013 Nov 20. Review.

PMID:
24269963
14.

Effects of pemetrexed, gefitinib, and their combination on human colorectal cancer cells.

Zhang G, Xie X, Liu T, Yang J, Jiao S.

Cancer Chemother Pharmacol. 2013 Oct;72(4):767-75.

PMID:
23959460
15.

Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy.

Kim ST, Park KH, Kim JS, Shin SW, Kim YH.

Cancer Res Treat. 2013 Mar;45(1):55-62. doi: 10.4143/crt.2013.45.1.55. Epub 2013 Mar 31.

16.

Predictive molecular classifiers in colorectal cancer.

Bohanes P, LaBonte MJ, Winder T, Lenz HJ.

Semin Oncol. 2011 Aug;38(4):576-87. doi: 10.1053/j.seminoncol.2011.05.012. Review.

PMID:
21810517
17.

Estimating preclinical efficacy targets utilizing cetuximab efficacy in KRAS mutant and wild-type colorectal cancer models.

Prewett M, Bassi R, Paz K, Amatulli M, Deevi D, Li H, Wang S, Witte L, Samakoglu S, Tonra JR.

Anticancer Res. 2011 Jun;31(6):2149-60.

PMID:
21737635
18.

Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.

Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA.

Ann Intern Med. 2011 Jan 4;154(1):37-49. doi: 10.7326/0003-4819-154-1-201101040-00006. Review.

PMID:
21200037
19.

[Current medicinal treatment of metastasized colorectal carcinoma].

Folprecht G.

Chirurg. 2010 Jun;81(6):507-15. doi: 10.1007/s00104-010-1892-8. Review. German.

PMID:
20574792
20.

New strategies for treatment of KRAS mutant metastatic colorectal cancer.

Prenen H, Tejpar S, Van Cutsem E.

Clin Cancer Res. 2010 Jun 1;16(11):2921-6. doi: 10.1158/1078-0432.CCR-09-2029. Epub 2010 May 11. Review.

Supplemental Content

Loading ...
Support Center